For research use only. Not for therapeutic Use.
Caracemide（Cat No.:I005572）is an antineoplastic agent studied for its potential in cancer treatment. It functions as a prodrug, metabolizing into active compounds that interfere with DNA synthesis and repair, leading to cell cycle arrest and apoptosis in rapidly dividing tumor cells. Caracemide has shown activity against various malignancies in preclinical studies, although its clinical development was limited due to toxicity concerns. It remains a valuable compound in oncology research for studying DNA-damaging agents, mechanisms of cytotoxicity, and the development of safer, more effective chemotherapeutic drugs.
| Catalog Number | I005572 |
| CAS Number | 81424-67-1 |
| Synonyms | NSC-253272; NSC 253272; NSC253272; Caracemide;N-(methylcarbamoyl)-N-((methylcarbamoyl)oxy)acetamide |
| Molecular Formula | C6H11N3O4 |
| Purity | ≥95% |
| Target | Anti-infection |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term ,or -20 °C for long term |
| IUPAC Name | [acetyl(methylcarbamoyl)amino] N-methylcarbamate |
| InChI | InChI=1S/C6H11N3O4/c1-4(10)9(5(11)7-2)13-6(12)8-3/h1-3H3,(H,7,11)(H,8,12) |
| InChIKey | JURAJLFHWXNPHG-UHFFFAOYSA-N |
| SMILES | CC(=O)N(C(=O)NC)OC(=O)NC |
| Reference | </br>1:A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer. Witte RS, Lipsitz S, Goodman TL, Asbury RF, Wilding G, Strnad CM, Smith TJ, Haller DG.Invest New Drugs. 1999;17(2):173-7. PMID: 10638488 </br>2:A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer. Witte RS, Hsieh P, Elson P, Oken MM, Trump DL.Invest New Drugs. 1996;14(4):409-13. PMID: 9157078 </br>3:Studies on the metabolic fate of caracemide, an experimental antitumor agent, in the rat. Evidence for the release of methyl isocyanate in vivo. Slatter JG, Davis MR, Han DH, Pearson PG, Baillie TA.Chem Res Toxicol. 1993 May-Jun;6(3):335-40. PMID: 8318655 </br>4:Caracemide, a site-specific irreversible inhibitor of protein R1 of Escherichia coli ribonucleotide reductase. Larsen IK, Cornett C, Karlsson M, Sahlin M, Sjöberg BM.J Biol Chem. 1992 Jun 25;267(18):12627-31. PMID: 1618768 Free Article</br>5:Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study. Lad T, Schor J, Mullane M, Carroll R, Chernicoff D, Blough R, Weidner L.Invest New Drugs. 1992 Apr;10(1):27-8. No abstract available. PMID: 1318870 </br>6:In vivo and in vitro cholinesterase inhibitor property of the antitumor agent caracemide. Buccafusco JJ, Smith MD.Res Commun Chem Pathol Pharmacol. 1990 Feb;67(2):219-27. PMID: 2333410 </br>7:The effect of the experimental antitumor agent caracemide on brain choline acetyltransferase. Ho BT, Tansey LW, Feiffer R, Newman RA, Farquhar D, Fields WS, Krakoff IH.J Neurosci Res. 1988;19(1):119-21. PMID: 3343703 </br>8:In vitro cytotoxicity of caracemide alone and in combination with hydroxyurea or iron-chelating agents in human chronic myeloid leukemia cells and murine tumors. Satyamoorthy K, Chitnis MP, Advani SH.Neoplasma. 1988;35(1):27-35. PMID: 3162554 </br>9:Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusion. Pazdur R, Chabot GG, Baker LH.Invest New Drugs. 1987 Dec;5(4):365-71. PMID: 3436742 </br>10:Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. Belani CP, Eisenberger M, Van Echo D, Hiponia D, Aisner J.Cancer Treat Rep. 1987 Nov;71(11):1099-100. No abstract available. PMID: 2824047 |
